• Northlands Road, Magee Campus

    BT48 7JL Londonderry

    United Kingdom

  • 957 Citations
  • 15 h-Index
20022019
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

After his Biochemistry degree, Dr David Gibson worked at Randox Laboratories Ltd, where he was responsible for designing and commercialising novel biochip array diagnostic tests.

He was awarded a PhD in 2001 from the Centre for Cancer Research and Cell Biology, Queen’s University Belfast (QUB), for research which exposed the role of cysteine proteinases in brain tumour invasion.

During a Wellcome Trust Fellowship Dr Gibson investigated the role of inflammation in a hypoxia driven model of diabetic retinopathy at the Centre of Vision and Vascular Science, QUB.

Since 2003 Dr Gibson focused his research efforts on the discovery and validation of protein biomarkers which could improve the management of arthritis patients.

During his time at the Rooney laboratory in the Centre of Infection and Immunity, QUB he spearheaded the use of proteomic and bioinformatics strategies to discover clinically useful biomarker candidates. He also identified post translational modifications in the Vitamin D binding protein that may act as a modulator of inflammation in juvenile arthritis patients.

In 2009, Dr Gibson was awarded a prestigious travel fellowship from Arthritis Research UK to conduct mass spectrometry based research at the Duncan laboratory at the University of Colorado, Denver over two years.

 

 

Research Interests

 

In 2013 Dr Gibson took up his post as Lecturer in Stratified Medicine and his research is focused on adult rheumatoid arthritis (RA). He is particularly interested in the development of new prognostic and predictive tools to improve the clinical management of arthritis patients.

He employs novel mass spectrometry based methods to robustly identify and quantify disease associated proteins in blood. He is also interested in the application of protein array technologies for autoantibody screening and flow cytometry in measuring B- and T-cell activation.

He has established research programmes in three key areas:
1. Biomarkers of response to disease modifying anti-rheumatic drugs.
2. Mechanisms of cannabinoid compounds on inflammation and pain in a model of arthritis.
3. Alternate blood sampling methods to support home based monitoring of arthritis.

Ultimately, Dr Gibsons group will develop novel monitoring tools to help clinicians target those patients who do not respond well to current therapeutics or develop drug resistance over time. This could allow earlier more effective treatments in RA patients, thus preventing joint damage and reducing disability.

 

Teaching Interests

 

1. Introduction to Pharmacogenomics and Stratified Medicine
2. Inflammatory and Immunological Disease
3. Genomics, Proteomics and Metabolomics
4. Disease and Treatment 2

Administrative Roles

BSc Associate Course Director

Keywords

  • RZ Other systems of medicine
  • QH301 Biology

Fingerprint Dive into the research topics where David Gibson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Juvenile Arthritis Medicine & Life Sciences
Proteomics Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Proteome Medicine & Life Sciences
Proteins Medicine & Life Sciences
Synovial Fluid Medicine & Life Sciences
Joints Medicine & Life Sciences
Inflammation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

Can the endocannabinoid receptor system reduce neuronal inflammation in arthritis?

Gibson, D., Murray, EK. & Watterson, S., 23 May 2019, Brain and Neuroscience Advances: BNA Festival of Neuroscience 2019. Vol. 3. PM148 (PP)

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Open Access
Cannabidiol
Endocannabinoids
Arthritis
Inflammation
Rheumatoid Arthritis

Stratifying patients with inflammatory diseases based on treatment response

Prasad, B., Gibson, D., McGeough, C., Eakin, A., Ahmed, T., Small, D., Gardiner, P., Pendleton, A., Wright, G., Bjourson, AJ. & Shukla, P., 2019.

Research output: Contribution to conferencePoster

58 Citations (Scopus)

Age and Age-related Diseases: Role of Inflammation Triggers and Cytokines

Rea, M. I., Gibson, D. S., McGilligan, V. E., McNerlan, S. E., Alexander, H. D. & Ross, O. A., 9 Apr 2018, In : Frontiers in Immunology. 2018

Research output: Contribution to journalArticle

Open Access
File
Inflammasomes
Cytokines
Inflammation
Phenotype
Autophagy
File
Interleukin-1beta
Osteoarthritis
Hand
Inflammasomes
Interleukin-17
16 Citations (Scopus)

NLRP3 as a potentially novel biomarker for the management of osteoarthritis

McAllister, M., El Chemaly, M., Eakin, A. J., Gibson, D. S. & McGilligan, V. E., 31 May 2018, In : Osteoarthritis and Cartilage. 26, 5, p. 612–619 8 p.

Research output: Contribution to journalArticle

Open Access
File
Osteoarthritis
Biomarkers
Inflammasomes
Disease Management
Matrix Metalloproteinases

Press / Media

All you ever wanted to know about arthritis

David Gibson

18/01/19

1 media contribution

Press/Media: Expert Comment

Thesis

Discovery of circulating DMARD response biomarkers in rheumatoid arthritis

Author: Eakin, A., Apr 2018

Supervisor: Gibson, D. (Supervisor) & Bjourson, A. (Supervisor)

Student thesis: Doctoral Thesis

Towards a personalised medicine strategy to reduce prostate cancer risk in men

Author: Yankova, E., May 2018

Supervisor: Mc Dowell, A. (Supervisor) & Gibson, D. (Supervisor)

Student thesis: Doctoral Thesis